Dr. Kaitlin A. Ryan, M.D.
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
At a glance
- Medical school
- Temple University School of Medicine (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: Temple University School of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
TN license 57489 -
Pediatric Cardiology Physician
TN license 57489 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Medical groups
- Ut Lebonheur Pediatric Specialists, Inc. (166 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 4 companies reported 4 payments worth $320 in total to this clinician.
| Abiomed | $136 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $132 |
| Merck Sharp & Dohme LLC | $35.00 |
| Actelion Pharmaceuticals US, Inc. | $16.69 |
| Food and Beverage | $320 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $30,862 in research payments for these studies, mostly to the institutions running them.
- A Phase 2,3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants with Heart Failure due to Systemic Left Ventricul…
Merck Sharp & Dohme LLC - A Phase 3, Single-arm, Open-label Extension of the Vericiguat VALOR Study in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction VALOR EXT
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.